

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants:** Dong-Mei Feng

**Serial No.:** To Be Assigned

**Case No.:** 20183YCA

**Filed:** August 8, 2001

**For:** CONJUGATES USEFUL IN THE TREATMENT OF  
PROSTATE CANCER

**Art Unit:**

To Be Determined

**Examiner:**

To Be Determined

Assistant Commissioner for Patents  
Washington, D.C. 20231

**LETTER**

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases:  
Application Disclosures Containing Nucleotide and/or Amino Acid Sequences, the signature page and  
following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence  
Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 20183Y.

Respectfully submitted,

By: 

David A. Muthard  
Registration No. 35,297  
Attorney for Applicants


Merck & Co., Inc.  
P.O. Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-3903

Date: August 8, 2001

Express Mail Certificate

Date of Deposit August 8, 2001  
Express Mail No. EL523905034US

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as Express Mail "Post Office to Addressee"  
before 5 p.m. on the above date in an envelope addressed to  
Assistant Commissioner for Patents, Washington, D.C. 20231

Mailed By   
Date August 8, 2001